Suvi Sorsa has extensive experience in cancer biology and gene therapy, especially with oncolytic viruses. She has published 17 scientific papers with an emphasis on tumor immunotherapy. She completed her PhD thesis studies at the Cancer Gene Therapy Group, University of Helsinki and has previous biotechnology experience from Ark Therapeutics Ltd, Kuopio, Finland. In January 2015, Suvi joined TILT Biotherapeutics Ltd as Head of Research and Development. She will be responsible for preclinical research and translation into clinical development.